"Revive Therapeutics Phase 3 Trial For COVID Officially Enters The Regulatory Funnel"
On Sep 15, 2022 Share
On Wednesday, Revive Therapeutics Ltd. (CNSX: RVV) (OTCMKTS: RVVTF) took another step towards a resolution of its current Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19. The company announced that pursuant to its intention to pursue new primary symptoms endpoints, it has officially filed an amended protocol to the U.S. Food & Drug Administration.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.